ArticleFrontiers in immunology2017
Global Assessment of Dengue Virus-Specific CD4
Open access · goldAbstract read
In one paragraph
Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
10.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 81 citations in OpenAlex.
- Serotype skewing and immune imprinting shape response to the tetravalent dengue virus Qdenga vaccine.medRxiv : the preprint server for health sciences · 2026Article
- TTV Viremia and Immune Responses Following Vaccination Against Mpox and Dengue Viruses.Vaccines · 2026Article
- Enhancing, controlling, and sterilizing dengue immunity and the development of broadly protective responses.medRxiv : the preprint server for health sciences · 2026Article
- Design of a tetravalent dengue vaccine incorporating T-cell epitopes from NS3 and NS5 proteins and B-cell epitopes from the envelope protein using an immunoinformatics approach.Frontiers in cellular and infection microbiology · 2026Article
- Peptide MegaPools Approach to Evaluate the Dengue-Specific CD4 and CD8 T-Cell Response.Pathogens (Basel, Switzerland) · 2025Article
- Identification of immunogenic and cross-reactive chikungunya virus epitopes for CD4Nature communications · 2025Article
- Chikungunya virus-specific CD4Cell reports. Medicine · 2025Article
- Distinct features of a peripheral T helper subset that drives the B cell response in dengue virus infection.Cell reports · 2025Article
- Frequency of dengue virus-specific T cells is related to infection outcome in endemic settings.JCI insight · 2025Article
- Article
- Article
- The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma.Nature communications · 2023Article
- Preclinical proof of concept of a tetravalent lentiviral T-cell vaccine against dengue viruses.Frontiers in immunology · 2023Article
- Antigen-specificity measurements are the key to understanding T cell responses.Frontiers in immunology · 2023Review
- ZIKV-envelope proteins induce specific humoral and cellular immunity in distinct mice strains.Scientific reports · 2022Article
- Infection order outweighs the role of CD4iScience · 2022Article
- Transcriptomics of Acute DENV-Specific CD8+ T Cells Does Not Support Qualitative Differences as Drivers of Disease Severity.Vaccines · 2022Article
- Variances in Antiviral Memory T-Cell Repertoire of CD45RA- and CD62L-Depleted Lymphocyte Products Reflect the Need of Individual T-Cell Selection Strategies to Reduce the Risk of GvHD while Preserving Antiviral Immunity in Adoptive T-Cell Therapy.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2022Article
- Article
- Bioinformatic and Experimental Analysis of T Cell Immune Reactivity to SARS-CoV-2 and its Variants.Frontiers in bioinformatics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 16 institutions in 9 countries.
Alba GrifoniDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.
Michael A AngeloDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.
Benjamin LopezDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.
Patrick H O'RourkeDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.
John SidneyDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.
Cristhiam CerpasLaboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministerio de Salud, Managua, Nicaragua.
Angel BalmasedaLaboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministerio de Salud, Managua, Nicaragua.
Cassia G T SilveiraDivision of Clinical Immunology and Allergy, School of Medicine, University of São Paulo, São Paulo, Brazil.
Alvino MaestriDivision of Clinical Immunology and Allergy, School of Medicine, University of São Paulo, São Paulo, Brazil.
Priscilla R CostaDivision of Clinical Immunology and Allergy, School of Medicine, University of São Paulo, São Paulo, Brazil.
Anna P DurbinJohns Hopkins University Bloomberg School of Public Health, Baltimore, MD, United States.
Sean A DiehlVaccine Testing Center, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, United States.
Elizabeth PhillipsInstitute for Immunology and Infectious Diseases, Murdoch University, Perth, WA, Australia.
Simon MallalInstitute for Immunology and Infectious Diseases, Murdoch University, Perth, WA, Australia.
Aruna D De SilvaDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.
Godwin NchindaChantal BIYA International Reference Centre for Research on the Prevention and Management of HIV/AIDS CIRCB, Yaoundé, Cameroon.
Celine NkenfouChantal BIYA International Reference Centre for Research on the Prevention and Management of HIV/AIDS CIRCB, Yaoundé, Cameroon.
Matthew H CollinsDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.
Aravinda M de SilvaDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.
Mei Qiu LimEmerging Infectious Disease Programme, Duke-NUS Medical School, Singapore, Singapore.
Paul A MacaryImmunology Programme, Department of Microbiology and Immunology, Life Sciences Institute, National University of Singapore, Singapore, Singapore.
Filippo TatulloInstitute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom.
Tom SolomonInstitute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom.
Vijaya SatchidanandamDepartment of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India.
Anita DesaiNeurovirology, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India.
Vasanthapram RaviNeurovirology, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India.
Josefina ColomaDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, United States.
Lance TurtleInstitute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom.
Laura RivinoEmerging Infectious Disease Programme, Duke-NUS Medical School, Singapore, Singapore.
Esper G KallasDivision of Clinical Immunology and Allergy, School of Medicine, University of São Paulo, São Paulo, Brazil.
Bjoern PetersDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.
Eva HarrisDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, United States.
Alessandro SetteDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.
Daniela WeiskopfDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.
La Jolla Institute for Immunology · USUniversidade de São Paulo · BRCentre International De Reference Chantal Biya · CMDuke-NUS Medical School · SGHealth Protection Research Unit in Emerging and Zoonotic Infections at University of Liverpool · GBMinisterio de Salud · NINational Institute of Mental Health and Neurosciences · INUniversity of California, Berkeley · USUniversity of North Carolina at Chapel Hill · USIndian Institute of Science Bangalore · INJohns Hopkins University · USMurdoch University · AUNational University of Singapore · SGUniversity of Liverpool · GBUniversity of Vermont · USVanderbilt University Medical Center · US
Funding
T Cell Responses Following DENV Natural Infections and Live-Attenuated Dengue Virus VaccinationP01AI106695 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI Eva Harris · 2015 to 2026
$34.1MUnderstanding and preventing HLA-associated drug reactionsP50GM115305 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DENNY, JOSHUA C. · 2015 to 2019
$13.0MDepartment of Health EME/12/205/28Department of Health IS-HPU-1112-10117Department of Health RP-PG-0108-10048Medical Research Council G116/194Medical Research Council MC_PC_15096NIAID NIH HHS HHSN272200900042CNIAID NIH HHS P01 AI106695NIGMS NIH HHS P50 GM115305Wellcome Trust 205228/Z/16/Z
Abstract
backgroundDengue is a major public health problem worldwide. Assessment of adaptive immunity is important to understanding immunopathology and to define correlates of protection against dengue virus (DENV). To enable global assessment of CD4
methodsHLA class II epitopes in the population of Managua were identified by an
resultsWe detected responses directed against a total of 431 epitopes, representing all 4 DENV serotypes, restricted by 15 different HLA-DRB1 alleles. The responses were associated with a similar pattern of protein immunodominance, overall higher magnitude of responses, as compared to what was observed previously in the Sri Lanka region. Based on these epitope mapping studies, we designed a DENV CD4 MP
conclusionThe DENV CD4 MP
Indexed as
adaptive immunityCD4+ T cellsdengue virusepitopeHLA
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.